Objective: To determine the efficacy of Hyoscine butyl bromide versus drotaverine hydrochloride, in term of time duration of active phase of first stage of labor among primiparous women. Material and Methods: This comparative study was performed at the Obstetrics & Gynecology Department, Lady Willingdon Hospital, Lahore within the duration of 6 months from September 2017 to February 2018. All the primigravida females with 38-42 weeks of gestational age from the last menstrual period (LMP) with singleton pregnancy and cephalic presentation, and in the active-phase of first-stage >3cm dilatation were registered in the study. Patients were grouped into two categories. Group 'A' patients were administered with 10 mg I/v Hyoscine Butyl bromide at 3-4cm dilatation and doses were repeated consecutively after each hour up to a maximum concentration of 3 doses, in terms of cervical dilatation. Group-B was directed with 40mg of Drotaverine I/v at 3-4cm dilatation, doses were repeated consecutively after 2 hours according to cervical dilatation up to a maximum concentration of 3 injections. After every half hour, monitoring of uterine contractions, vital signs and fetal cardiac rate was performed. Labor progress was estimated by cervicogram. The primary-outcome i.e. course of time of active phase of labor's first stage in both groups was documented in pre-intended proforma. Results: Overall 100 cases were enrolled (50 cases per group). Mean age of group A was 27.3+3.4 years and 25.7+2.8 years of group B. Mean durations for active-phase of labor's first stage was significantly lesser among Hyoscine Butyl bromide administered patients contrasted to drotaverine hydrochloride administrated patients as; 159.42+6.22 minutes in group “A” and 199.77+8.43 minutes in group B, P-value of 0.008. Conclusion: It was concluded that both drugs showed favorable efficacy of first stage labour's active phase time duration among primiparous patients, while the Hyoscine Butyl Bromide is more effective in reduction of this time duration as compared to Drotaverine hydrochloride.